FAQ: Intelligent Bio Solutions Inc.'s Multilingual Digital Expansion and Global Sales Growth

What is Intelligent Bio Solutions Inc. (INBS) expanding?

INBS is expanding its international footprint by launching localized websites in Arabic, Italian, and Spanish to support its growth into Latin America, the Middle East, and Southern Europe.

Why is INBS launching multilingual websites?

The multilingual rollout aims to remove barriers to digital engagement and facilitate sales pipeline development in regions with over 1.4 billion people, addressing the growing demand for workplace safety and compliance solutions.

How does INBS’s flagship product work?

INBS’s flagship product is a fingerprint sweat-based drug screening system, currently used by over 450 clients in 24 countries, offering a rapid, non-invasive testing solution.

When does INBS plan to launch in the U.S. market?

INBS plans a U.S. market launch in 2025 as part of its strategy to develop additional biosensor applications.

Where is INBS’s expansion targeted?

The expansion targets Latin America, the Middle East, and Southern Europe, regions with significant commercial potential for INBS’s products.

Who is affected by INBS’s expansion?

Over 1.4 billion people across the targeted regions, along with businesses seeking non-invasive workplace drug testing and compliance tools, are affected by INBS’s expansion.

What are the implications of INBS’s multilingual digital rollout?

The rollout is expected to boost commercial activity in high-potential regions, enhancing access to INBS’s innovative testing solutions and supporting global sales growth.

How can investors stay updated on INBS’s developments?

Investors can find the latest news and updates relating to INBS in the company’s newsroom at https://ibn.fm/INBS.

What makes INBS’s drug screening system unique?

INBS’s system is unique due to its non-invasive, fingerprint sweat-based technology, offering a rapid solution for drug testing that is currently utilized by a wide range of clients globally.